Antagonist-radioligand binding to D2L-receptors in intact cells

Biochemical Pharmacology

Volumn 75, Issue 11, 2008, Pages 2192-2203

  Packeu, Ann ^a   De Backer, Jean Paul ^a   Van Liefde, Isabelle ^a   Vanderheyden, Patrick M L ^a   Vauquelin, Georges ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Dopamine receptor; Intact cells; Raclopride; Radioligand binding; Spiperone

Indexed keywords

DOPAMINE 2 RECEPTOR; RACLOPRIDE; SPIPERONE; TRITIUM;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DISSOCIATION; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; DEUTERIUM; DOPAMINE ANTAGONISTS; HUMANS; LIGANDS; RACLOPRIDE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; SPIPERONE; TIME FACTORS;

EID: 43049137653     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.03.001     Document Type: Article

References (65)

1. Picetti R., Saiardi A., Abdel Samad T., Bozzi Y., Baik J.H., and Borrelli E. Dopamine D2 receptors in signal transduction and behavior. Crit Rev Neurobiol 11 (1997) 121-142
2. Kebabian J.W., and Calne D.B. Multiple receptors for dopamine. Nature 277 (1979) 93-96
3. Stoof J.C., and Kebabian J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294 (1981) 366-368
4. Velasco M., and Luchsinger A. Dopamine: pharmacologic and therapeutic aspects. Am J Ther 5 (1998) 37-43
5. Dal Toso R., Sommer B., Ewert M., Herb A., Pritchett D.B., Bach A., et al. The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J 8 (1989) 4025-4034
6. Usiello A., Baik J.H., Rouge-Pont F., Picetti R., Dierich A., LeMeur M., et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408 (2000) 199-203
7. Wang Y., Xu R., Sasaoka T., Tonegawa S., Kung M.P., and Sankoorikal E.B. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J Neurosci 20 (2000) 8305-8314
8. Lindgren N., Usiello A., Goiny M., Haycock J., Erbs E., Greengard P., et al. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci USA 100 (2003) 4305-4309
9. Montmayeur J.P., Guiramand J., and Borrelli E. Preferential coupling between dopamine D2 receptors and G-proteins. Mol Endocrinol 7 (1993) 161-170
10. Senogles S.E. The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins. J Biol Chem 269 (1994) 23120-23127
11. Guiramand J., Montmayeur J.P., Ceraline J., Bhatia M., and Borrelli E. Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J Biol Chem 270 (1995) 7354-7358
12. Xu R., Hranilovic D., Fetsko L.A., Bucan M., and Wang Y. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Mol Psychiatry 7 (2002) 1075-1082
13. Seeman P., Chau-Wong M., Tedesco J., and Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72 (1975) 4376-4380
14. Creese I., Burt D.R., and Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192 (1976) 481-483
15. Deutch A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J Neural Transm Gen Sect 91 (1993) 197-221
16. Kapur S., and Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Pychiatry 158 (2001) 360-369
17. Swinney D.C. Biochemical mechanisms of drug action: what does it take for success?. Nat Rev Drug Discov 3 (2004) 801-808
18. Swinney D.C. Can binding kinetics translate to a clinically differentiated drug? From theory to practice. Lett Drug Des Discov 3 (2006) 569-574
19. Copeland R.A., Pompliano D.L., and Meek T.D. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5 (2006) 730-739
20. Oliveira C.R., Lima M.C., Carvalho C.A., Leysen J.E., and Carvalho A.P. Partition coefficients of dopamine antagonists in brain membranes and liposomes. Biochem Pharmacol 38 (1989) 2113-2120
21. Makriyannis A., Tian X., and Guo J. How lipophilic cannabinergic ligands reach their receptor sites. Prostaglandins Other Lipid Mediat 77 (2005) 210-218
22. Niznik H.B., Grigoriadis D.E., Pri-Bar I., Buchman O., and Seeman P. Dopamine D2 receptors selectively labelled by a benzamide neuroleptic: [3H]-YM-09151-2. Naunyn Schmiedebergs Arch Pharmacol 329 (1985) 333-343
23. Terai M., Hidaka K., and Nakamura Y. Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine d-2 receptor binding to rat striatum. Eur J Pharmacol 173 (1989) 177-182
24. Seeman P., Guan H.C., Civelli O., Van Tol H.H., Sunahara R.K., and Niznik H.B. The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. Eur J Pharmacol 227 (1992) 139-146
25. Ng G.Y., O'Dowd B.F., Lee S.P., Chung H.T., Brann M.R., Seeman P., et al. Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 227 (1996) 200-204
26. Vile J.M., D'Souza U.M., and Strange P.G. [3H]nemonapride and [3H]spiperone label equivalent numbers of D2 and D3 dopamine receptors in a range of tissues and under different conditions. J Neurochem 64 (1995) 940-943
27. Malmberg A., Jerning E., and Mohell N. Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites. Eur J Pharmacol 303 (1996) 123-128
28. Hall H., Wedel I., Halldin C., Kopp J., and Farde L. Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes. J Neurochem 55 (1990) 2048-2057
29. Hara M., Tozawa F., Itazaki K., Mihara S., and Fujimoto M. Endothelin ET(B) receptors show different binding profiles in intact cells and cell membrane preparations. Eur J Pharmacol 345 (1998) 339-342
30. Fierens F.L., Vanderheyden P.M., Roggeman C., Vande Gucht P., De Backer J.P., and Vauquelin G. Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations. Biochem Pharmacol 63 (2002) 1273-1279
31. Verheijen I., Vanderheyden P.M., De Backer J.P., Bottari S., and Vauquelin G. Antagonist interaction with endogenous AT(1) receptors in human cell lines. Biochem Pharmacol 64 (2002) 1207-1214
32. Vauquelin G., Morsing P., Fierens F.L., De Backer J.P., and Vanderheyden P.M. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. Biochem Pharmacol 61 (2001) 277-284
33. Itokawa M., Toru M., Ito K., Tsuga H., Kameyama K., Haga T., et al. Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells. Mol Pharmacol 49 (1996) 560-566
34. Norman J.A., Drummond A.H., and Moser P. Inhibition of calcium-dependent regulator-stimulated phosphodiesterase activity by neuroleptic drugs is unrelated to their clinical efficacy. Mol Pharmacol 16 (1979) 1089-1094
35. Martres M.P., Bouthenet M.L., Sales N., Sokoloff P., and Schwartz J.C. Widespread distribution of brain dopamine receptors evidenced with [125I]iodosulpride, a highly selective ligand. Science 228 (1985) 752-755
36. Kim K.M., Valenzano K.J., Robinson S.R., Yao W.D., Barak L.S., and Caron M.G. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled kinases and beta-arrestins. J Biol Chem 276 (2001) 409-414
37. Armstrong D., and Strange P.G. Dopamine D2 receptor dimer formation: evidence from ligand binding. J Biol Chem 276 (2001) 22621-22629
38. Vivo M., Lin H., and Strange P.G. Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor. Mol Pharmacol 69 (2006) 226-235
39. Dewar K.M., Montreuil B., Grondin L., and Reader T.A. Dopamine D2 receptors labelled with [3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity. J Pharmacol Exp Ther 250 (1989) 696-706
40. Lepiku M., Rinken A., Järv J., and Fuxe K. Kinetic evidence for isomerization of the dopamine receptor-raclopride complex. Neurochem Int 28 (1996) 591-595
41. de Chaffoy De Courcelles D. The serotonin-S2 receptor: a receptor-transducer coupling model to explain insurmountable antagonist effects. Drug Dev Res 8 (1986) 173-178
42. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16 (1995) 232-238
43. Vauquelin G., and Van Liefde I. G protein-coupled receptors: a count of 1001 conformations. Fundam Clin Pharmacol 19 (2005) 45-56
44. Chatterjee T.K., Scott C.E., Vazquez D.M., and Bhatnagar R.K. Interaction of [3H]spiperone with rat striatal dopamine D-2 receptors: kinetic evidence for antagonist-induced formation of ternary complex. Mol Pharmacol 33 (1988) 402-413
45. Vauquelin G., and Szczuka A. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation. Neurochem Int 51 (2007) 254-260
46. DeMeyts P., Bainco A.R., and Roth J. Site-site interactions among insulin receptors. Characterization of the negative cooperativity. J Biol Chem 251 (1976) 1877-1888
47. Park L.S., Friend D.J., Schmierer A.E., Dower S.K., and Namen A.E. Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7-dependent cell line. J Exp Med 171 (1990) 1073-1089
48. Limbird L.E. Cell surface receptors: a short course on theory and methods (1996), Kulwer Academic Publishers, Norwell, MA
49. Gill R., Verma C., Wallach B., Urso B., Pitts J., Wollmer A., et al. Modelling of the disulphide-swapped isomer of human insulin-like growth factor-1: implications for receptor binding. Protein Eng 12 (1999) 297-303
50. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1 (2002) 198-210
51. Christopoulos A., and Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54 (2002) 323-374
52. Gopalakrishnan M., Forsten-Williams K., Nugent M.A., and Täuber U.C. Effects of receptor clustering on ligand dissociation kinetics: theory and simulations. Biophys J 89 (2005) 3686-3700
53. Fierens F., Vanderheyden P.M., De Backer J.P., and Vauquelin G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. Eur J Pharmacol 367 (1999) 413-422
54. Sutter A., Riopelle R.J., Harris-Warrick R.M., and Shooter E.M. Nerve growth factor receptors. Characterization of two distinct classes of binding sites on chick embryo sensory ganglia cells. J Biol Chem 254 (1979) 5972-5982
55. Berg H.C., and Purcell E.M. Physics of chemoreception. Biophys J 20 (1977) 193-219
56. DeLisi C. The effect of cell size and receptor density on ligand-receptor reaction rate constants. Mol Immunol 18 (1981) 507-511
57. Shoup D., and Szabo A. Role of diffusion in ligand binding to macromolecules and cell-bound receptors. Biophys J 40 (1982) 33-39
58. Goldstein B., Posner R.G., Torney D.C., Erickson J., Holowka D., and Baird B. Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody. Biophys J 56 (1989) 955-966
59. Axelrod D., and Wang M.D. Reduction-of-dimensionality kinetics at reaction-limited cell surface receptors. Biophys J 66 (1994) 588-600
60. Tian X., Guo J., Yao F., Yang D.P., and Makriyannis A. The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J Biol Chem 280 (2005) 29788-29795
61. Zoumpoulakis P. Seeking the active site of the AT1 receptor for computational docking studies. Drug Des Rev 2 (2005) 537-545
62. Lynch D.L., and Reggio P.H. Cannabinoid CB1 receptor recognition of endocannabinoids via the lipid bilayer: molecular dynamics simulations of CB1 transmembrane helix 6 and anandamide in a phospholipid bilayer. J Comput Aided Mol Des 20 (2006) 495-509
63. Goldstein B. Cell surface receptors: models for binding, aggregation and signal initiation. Part A. Ligand-receptor binding and cell surface receptor dynamics, http://www.samsi.info/200405/compbio/SAMSInotes032405.pdf, 2005
64. Gazi L., Wurch T., Lopéz-Giménez J.F., Pauwels P.J., and Strange P.G. Pharmacological analysis of a dopamine D(2short): G(alphao) fusion protein expressed in Sf9 cells. FEBS Lett 545 (2003) 155-160
65. Kapur S., and Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications of atypical antipsychotic action. J Psychiatry Neurosci 25 (2000) 161-166